RAPT Therapeutics Past Earnings Performance
Past criteria checks 0/6
RAPT Therapeutics's earnings have been declining at an average annual rate of -23.3%, while the Biotechs industry saw earnings growing at 11.8% annually. Revenues have been declining at an average rate of 5.3% per year.
Key information
-23.3%
Earnings growth rate
72.7%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -5.3% |
| Return on equity | -90.2% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How RAPT Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -118 | 28 | 100 |
| 31 Dec 23 | 0 | -117 | 26 | 101 |
| 30 Sep 23 | 0 | -109 | 25 | 94 |
| 30 Jun 23 | 0 | -99 | 23 | 83 |
| 31 Mar 23 | 1 | -93 | 21 | 76 |
| 31 Dec 22 | 2 | -84 | 20 | 67 |
| 30 Sep 22 | 2 | -79 | 20 | 62 |
| 30 Jun 22 | 3 | -76 | 18 | 61 |
| 31 Mar 22 | 3 | -73 | 17 | 60 |
| 31 Dec 21 | 4 | -69 | 16 | 57 |
| 30 Sep 21 | 4 | -64 | 15 | 54 |
| 30 Jun 21 | 5 | -60 | 14 | 51 |
| 31 Mar 21 | 5 | -56 | 13 | 49 |
| 31 Dec 20 | 5 | -53 | 13 | 45 |
| 30 Sep 20 | 4 | -53 | 12 | 45 |
| 30 Jun 20 | 2 | -49 | 10 | 40 |
| 31 Mar 20 | 1 | -47 | 10 | 38 |
| 31 Dec 19 | 0 | -43 | 9 | 35 |
| 30 Sep 19 | 0 | -39 | 7 | 33 |
| 30 Jun 19 | 0 | -40 | 7 | 34 |
| 31 Mar 19 | 0 | -37 | 6 | 32 |
| 31 Dec 18 | 0 | -36 | 5 | 32 |
Quality Earnings: 0RA is currently unprofitable.
Growing Profit Margin: 0RA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0RA is unprofitable, and losses have increased over the past 5 years at a rate of 23.3% per year.
Accelerating Growth: Unable to compare 0RA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0RA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (2.9%).
Return on Equity
High ROE: 0RA has a negative Return on Equity (-90.23%), as it is currently unprofitable.